oxazepam has been researched along with Acute Confusional Senile Dementia in 27 studies
Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.
oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-nine elderly residents of long-term care facilities who had DSM-III diagnoses of dementia were studied in an 8-week randomized, double-blind comparison trial of haloperidol, oxazepam, and diphenhydramine to test the efficacy of these agents in the treatment of clinically significant behavioral disturbances in patients with dementia." | 5.06 | Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. ( Coccaro, EF; Duvvi, K; Giordani, B; Kramer, E; Nora, R; Patel, BM; Rice, CM; Thorne, A; Torres, J; Zemishlany, Z, 1990) |
| "Thiothixene was more effective than oxazepam and diphenhydramine." | 2.67 | A single-case-study method for treating resistiveness in patients with Alzheimer's disease. ( Herz, LR; Rheaume, Y; Ross, V; Volicer, L, 1992) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "1." | 1.27 | Oxazepam as a probe of hepatic metabolism in patients with Alzheimer's disease. ( Fisman, M; Fox, H; Inaba, T; Kalow, W; Merskey, H; Wong, C, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 21 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sang, Z | 11 |
| Li, Y | 11 |
| Qiang, X | 10 |
| Xiao, G | 7 |
| Liu, Q | 2 |
| Tan, Z | 12 |
| Deng, Y | 11 |
| Luo, L | 6 |
| Yang, X | 5 |
| Zheng, Y | 4 |
| Cao, Z | 6 |
| Su, F | 2 |
| Ai, J | 1 |
| Xu, R | 5 |
| Song, Q | 5 |
| Pan, W | 2 |
| Wang, K | 8 |
| Ma, Q | 4 |
| Yu, L | 4 |
| Yang, Y | 1 |
| Bai, P | 2 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Li, X | 1 |
| Liu, W | 7 |
| Wang, H | 4 |
| Ye, M | 2 |
| Han, X | 2 |
| Yang, J | 2 |
| Zhang, X | 2 |
| Liu, H | 4 |
| Yang, Z | 2 |
| Kumar, D | 1 |
| Gupta, SK | 1 |
| Ganeshpurkar, A | 1 |
| Gutti, G | 1 |
| Krishnamurthy, S | 1 |
| Modi, G | 1 |
| Singh, SK | 1 |
| Tian, C | 1 |
| Li, W | 1 |
| He, Y | 1 |
| Ye, C | 1 |
| Shi, J | 4 |
| Srivastava, P | 1 |
| Tripathi, PN | 1 |
| Sharma, P | 1 |
| Shrivastava, SK | 1 |
| Zhang, P | 3 |
| Zhu, G | 1 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Patel, M | 1 |
| Tang, BK | 1 |
| Grant, DM | 1 |
| Kalow, W | 2 |
| Herz, LR | 1 |
| Volicer, L | 1 |
| Ross, V | 1 |
| Rheaume, Y | 1 |
| Stern, RG | 1 |
| Duffelmeyer, ME | 1 |
| Zemishlani, Z | 1 |
| Davidson, M | 1 |
| Coccaro, EF | 1 |
| Kramer, E | 1 |
| Zemishlany, Z | 1 |
| Thorne, A | 1 |
| Rice, CM | 1 |
| Giordani, B | 1 |
| Duvvi, K | 1 |
| Patel, BM | 1 |
| Torres, J | 1 |
| Nora, R | 1 |
| Fisman, M | 1 |
| Inaba, T | 1 |
| Fox, H | 1 |
| Merskey, H | 1 |
| Wong, C | 1 |
1 review available for oxazepam and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
The use of benzodiazepines in the management of behavioral symptoms in demented patients.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Behavior; Humans; Oxazepam | 1991 |
2 trials available for oxazepam and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A single-case-study method for treating resistiveness in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Defense Mechanisms; Diphenhydramine; Double-Blind Method; Hospitalization; | 1992 |
Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Diphenhydramine; D | 1990 |
24 other studies available for oxazepam and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Rel | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stres | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Olanzapine and delirium: lesson from clinical practice.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Delirium; Depre | 2008 |
Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam.
Topics: Adult; Aged; Alzheimer Disease; Female; Glucuronates; Humans; Kinetics; Liver; Male; Metabolic Clear | 1995 |
Oxazepam as a probe of hepatic metabolism in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Female; Humans; Hydroxylation; Liver; Male; Oxazepam; Reference Values; Sch | 1988 |